A clinical trial to assess the effect on quality of life in post menoapausal osteoporotic women with salmon calcitonin nasal spray.
Phase 4
Completed
- Conditions
- Health Condition 1: null- postmenopausal osteoporosis
- Registration Number
- CTRI/2010/091/002958
- Lead Sponsor
- Glenmark Pharmaceuticals Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
a.Postmenopausal women between 45-65 years of age or surgical menopausal (oophorectomy) cases
b.Bone mineral density(BMD) values -2.5 SD in at least one region measured by Dual Energy X-ray absorptiometry (DEXA)
Exclusion Criteria
a.Presence of secondary causes of osteoporosis and other possible causes of back pain (fragility fracture ,bone metastasis or inflammatory spine disease such as spondylarthritis)
b.Use of medications that cause osteoporosis
c.Any contraindications for using salmon calcitonin or calcium
d.History of taking anti osteoporotic agents in the last month
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method